A Phase 1 interventional study of JY1001 and Placebo in Pain After Surgery, sponsored by Jemincare. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Jemincare · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 245 studies in Pain with a site in China — 65 open to participants now, 71 under way, 2 of them phase 3. Pain · China.
Among the 245 studies in Pain with a site in China, this one is the 168th largest by planned enrollment of the 210 interventional ones that give a count, is one of 23 that started in 2026, is one of 17 in phase 1, reaches primary completion later than 38 of the 70 other live ones, and was the 243rd registered.
10,071 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →65 of the 245 studies in Pain with a site in China are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in China
Ages 18+
Yingyong Zhou,MD,PhD · Sites in China
Ages 18+
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Children's Hospital of Fudan University · Sites in China
Ages 1–18
Lijiang Lv · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
245 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 27 · Phase 3 26 · Phase 4 30
First in 1992; this study’s year is marked. 23 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 66 across 8,507 interventional studies indexed under Pain.
Median enrollment 120 across the 210 interventional studies, 169 across the 34 observational. Of the 121 that completed or were terminated, 17 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 245 have an industry lead sponsor. The 10 most frequent:
Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.
Jemincare has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
29 of the studies in Pain with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07872826Phase 3The Third Xiangya Hospital of Central South UniversityA Clinical Trial Evaluating the Efficacy and Safety of Local Infiltration of RF16001 for Injection for Analgesia After Total Hip Arthroplasty in China | 2027-06-30 |
| NCT07533786Haisco Pharmaceutical Group Co., Ltd.A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery | 2026-11-22 |
| NCT06553495Jie ChenA Comparative Analysis of Intertransverse Nerve Block and Paravertebral Nerve Block in Endoscopic Hepatectomy | 2026-11-30 |
| NCT07557823Second Affiliated Hospital, School of Medicine, Zhejiang UniversityTranscutaneous Auricular Vagus Nerve Stimulation Combined With Cervical Epidural Injection for Cervical Radiculopathy | 2026-12-30 |
| NCT07099157Peking University Third HospitalEfficacy and Safety of Brivudine in the Treatment of Herpes Zoster | 2026-12-31 |
Add all 29 to your calendar (.ics) → With an account.
Among the 245 studies in Pain with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this dose esclation study is to evaluate the safety, tolerability, and PK characteristicsafter of a single dose of JY1001 injection in healthy participants. A total of 6 cohorts are planned to be evaluated. Each cohort will enroll 8 participants to receive JY1001 or placebo in 3:1 ratio.
This is a randomized, double-blind, placebo-controlled Phase I clinical trial to evaluate the safety, tolerability, and PK characteristics of a single dose of JY1001 in healthy participants.
Healthy participants will be randomized to receive JY1001 or placebo (8 participants each cohort, with a ratio of 3:1). The study includes 6 cohorts. JY1001 doses levels in each cohort will be 10 mg, 20 mg, 40 mg, 80 mg, 160 mg, and 320 mg, respectively. Eligible participants will stay at the study center one day before administration (D-1) and receive the drug at D1. They will be discharged on D4 (72 hours after administration).
Decisions on dose escalation to next cohort will be made by Safety Review Committee (SRC) consisting of investigators and sponsor representatives, based on all participants' safety and tolerability data up to 72 hours after administration and any available PK data of the previous cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: JY1001
Drug: Placebo
Participants will receive a single dose of JY1001 (10 mg, 20 mg, 40 mg, 80 mg, 160 mg, 320 mg) via IV at Day 1
Participants will receive a single dose of placebo via IV at Day 1
Adverse events (AEs)
Incidence of Adverse events (AEs)
Time frame: Day 1 to Day 4
Maximum concentration (Cmax)
Cmax was the highest concentration observed directly from data
Time frame: Day 1 to Day 4
Area under the concentration-time curve
Reflects the actual body exposure to drug after administration of sinlge and multiple dose
Time frame: Day 1 to Day 4
Time to Cmax (Tmax)
Tmax was the time to reach maximum observed plasma concentration
Time frame: Day 1 to Day 4
Elimination half-life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Day 1 to Day 4
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.
Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's planned 6 months is above that.
Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.